Literature DB >> 7779707

Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined.

D J Honess1, N M Bleehen.   

Abstract

The strategy of combining carbogen breathing and nicotinamide to overcome chronic and acute hypoxia respectively is being evaluated clinically. The effects of both agents individually and in combination on relative perfusion of 400-700 mm3 RIF-1 tumours and normal tissues were measured by 86Rb extraction. Carbogen breathing alone for 6 min increased relative tumour perfusion by 50-70% compared with control at flow rates of 50 to 200 ml min-1, but the effect was lost at 300 ml min-1. All flow rates also produced similar increases in relative perfusion of lung, of between 36% and 58%, and smaller increases in skin, of between 20% and 34%. The minimum breathing time at 150 ml min-1 to produce a significant increase in relative tumour perfusion was 4.5 min, and the effect was maintained up to 9 min. Nicotinamide alone at 1000 mg kg-1 60 min before assay did not alter relative tumour perfusion. Comparing the combination of nicotinamide with 6 min carbogen breathing at 150 ml min-1 with carbogen breathing alone showed no difference in relative tumour perfusion; increases were of 36% and 42% respectively. Nicotinamide-induced alterations in microcirculation associated with reduction of acute hypoxia have therefore not been detected by 86Rb extraction. The perfusion-enhancing effect of carbogen in this tumour is probably an important component of its radiosensitising ability, in addition to its known ability to increase the oxygen-carrying capacity of the blood, and should be taken into consideration in clinical studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779707      PMCID: PMC2033837          DOI: 10.1038/bjc.1995.229

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Carbogen breathing during radiation therapy-the Radiation Therapy Oncology Group Study.

Authors:  P Rubin; J Hanley; H M Keys; V Marcial; L Brady
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979 Nov-Dec       Impact factor: 7.038

2.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.

Authors:  R A Gatenby; H B Kessler; J S Rosenblum; L R Coia; P J Moldofsky; W H Hartz; G J Broder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

3.  Blood flow and oxygenation of tumors in mice. I. Effects of breathing gases containing carbon dioxide at atmospheric pressure.

Authors:  J A Kruuv; W R Inch; J A McCredie
Journal:  Cancer       Date:  1967-01       Impact factor: 6.860

4.  The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma.

Authors:  D W Siemann; R P Hill; R S Bush
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Sep-Oct       Impact factor: 7.038

5.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

6.  Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues.

Authors:  M R Horsman; D J Chaplin; J M Brown
Journal:  Radiat Res       Date:  1987-03       Impact factor: 2.841

7.  Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status.

Authors:  M R Horsman; P V Hansen; J Overgaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

8.  Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation.

Authors:  M R Horsman; D J Chaplin; J M Brown
Journal:  Radiat Res       Date:  1989-04       Impact factor: 2.841

9.  Oxygen, oxygen plus carbon dioxide, and radiation therapy of a mouse mammary carcinoma.

Authors:  H D Suit; N Marshall; D Woerner
Journal:  Cancer       Date:  1972-11       Impact factor: 6.860

10.  Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations.

Authors:  A Rojas; R J Hodgkiss; M R Stratford; M F Dennis; H Johns
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  7 in total

1.  Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?

Authors:  Dominick J O McIntyre; Franklyn A Howe; Christophe Ladroue; Fiona Lofts; Marion Stubbs; John R Griffiths
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-07       Impact factor: 3.333

2.  In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas.

Authors:  L M Rodrigues; R J Maxwell; P M McSheehy; C R Pinkerton; S P Robinson; M Stubbs; J R Griffiths
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging.

Authors:  S P Robinson; L M Rodrigues; A S Ojugo; P M McSheehy; F A Howe; J R Griffiths
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  The effects of hyperoxic and hypercarbic gases on tumour blood flow.

Authors:  T J Dunn; R D Braun; W E Rhemus; G L Rosner; T W Secomb; G M Tozer; D J Chaplin; M W Dewhirst
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Use of thymidine analogues to indicate vascular perfusion in tumours.

Authors:  A C Begg; I Hofland; I Van Der Pavert; B Van Der Schueren; K Haustermans
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

6.  The effects of host carbogen (95% oxygen/5% carbon dioxide) breathing on metabolic characteristics of Morris hepatoma 9618a.

Authors:  M Stubbs; S P Robinson; L M Rodrigues; C S Parkins; D R Collingridge; J R Griffiths
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.

Authors:  H Barthel; H Wilson; D R Collingridge; G Brown; S Osman; S K Luthra; F Brady; P Workman; P M Price; E O Aboagye
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.